KKR-backed Sapphiros, a private equity firm and is based in the United States, agreed to acquire Biocrucible, a biotechnology company, for $20m. “This is an incredibly exciting moment for myself and the whole Biocrucible team who have built an amazing new molecular detection biochemistry. We will push hard to bring the next generation of molecular detection products right to where they are needed – in the home, in the doctor’s surgery, and in low-resource settings. This is a very personal opportunity for me finally to realise my ambition to lead the diagnostics sector with advanced cutting-edge technology solutions. We intend to make molecular diagnostics as accessible as their-lower performance lateral flow cousins," Niall Armes, Biocrucible Founder and CSO.